

Contact

T +49 (0)89 747 266 0

F +49 (0)89 776 424

E Fux@maiwald.eu



Dr. Anja Fux

Associate
German Patent Attorney
European Patent Attorney
UPC Representative
M.Sc. Biochemistry

Anja has experience in worldwide patent portfolio strategy and management, including drafting and prosecuting patent applications, as well as defending and challenging patent rights in all areas of biochemistry, biotechnology, and pharmaceuticals, including antibodies, T cell receptors, personalized medicine, vaccines, gene therapy, tablet formulations, as well as the microbiome. She is also involved in the preparation of opinions on freedom-to-operate, infringement, and validity questions. After having passed the German patent attorney examination and the European qualifying examination in February and March 2023, Anja worked at the US law firm Sterne, Kessler, Goldstein & Fox in Washington, D.C., from May to December 2023. During her stay at Sterne Kessler, Anja was *inter alia* involved in preparing the patent defense in post grant review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB) of the USPTO, preparation of validity opinions, freedom-to-operate and patentability analysis, as well as drafting patent applications. She also gained insights into inter partes review (IPR) proceedings before the PTAB and appeal proceedings before the U.S. Court of Appeals for the Federal Circuit (CAFC). In September 2023, Anja passed the US patent bar examination to complement her German and European qualifications. During her time in the US, Anja gained a fundamental understanding of US patent law, which supplements her knowledge of European and German patent law. This allows her to advise clients on European and German patent matters in a global context, enabling her to build bridges between important jurisdictions for an optimum worldwide strategy. Anja received her bachelor's and master's degrees in biochemistry, as well as her PhD from the Technical University of Munich. Her PhD focused on all aspects of mass spectrometry-based proteomics, including bacterial and mammalian cell culture, as well as the statistical evaluation of mass spectrometric data.

CAREER

since 2024	Patent attorney at Maiwald
2023	Legal Trainee at Sterne Kessler Goldstein & Fox, Washington, D.C., US
2023	Patentassessor at Maiwald
2020 - 2023	Patent attorney trainee at Maiwald
2016 - 2019	Scientific assistant at the chair of organic chemistry II of the Technical University of Munich

EDUCATION

2024	Admitted to practice as German patent attorney
2024	Admitted to practice as European patent attorney

2023	Passed the US patent bar examination
2022	Internship at a patent litigation chamber at the district court Munich I
2020 - 2022	Studying law for patent attorneys at the University of Hagen
2016 - 2019	Doctoral degree in the field of bioorganic chemistry from the Technical University of Munich
2014 - 2016	Master's degree in biochemistry from the Technical University of Munich
2011 - 2014	Bachelor's degree in biochemistry from the Technical University of Munich

PRACTICE AREAS

- 製薬&バイオテクノロジー
- 特許&実用新案

SERVICES

- Patent prosecution and portfolio management
- Filing strategies and drafting patent applications
- Freedom-to-operate and validity opinions
- Opposition, appeal, and nullity proceedings
- Patent litigation

RECOGNITIONS

- Managing IP EMEA Awards 2025 - shortlisted as Rising Star of the Year

PUBLICATIONS

- Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025
- After two years of G 2/21 case law, is the interpretation now settling? Managing IP, 2025
- Patenting medical treatments in the US and Europe – a guide for practitioners, Managing IP 2024
- Podcast – Empowering women and nurturing young talent: Maiwald's commitment to equality and diversity, MIP, 2024
- Is the medical use disclosure standard different for novelty and sufficiency?, Managing IP, 2024
- Promoting women and young talent at MAIWALD, 2024
- Reliance on a purported technical effect for inventive step – Quo vadis “plausibility” after G 2/21? epi Information, 1/2024
- Products eligible for the medical use format under the EPC: new insights, Managing IP 2024
- T 0116/18 and a review after 10 months of G 2/21, Managing IP 2024

LANGUAGES

- German
- English